Approaches for Managing Dermatologic Adverse Events from Talquetamab in Multiple Myeloma

EP: 1.How Are Patients with Multiple Myeloma (MM) Diagnosed and Staged?

EP: 2.Overview of Relapsed/Refractory Multiple Myeloma

EP: 3.MonumenTAL-1: Talquetamab in Relapsed/Refractory MM

EP: 4.Talquetamab Safety Profile in Relapsed/Refractory MM

EP: 5.Clinical Strategies for Adverse Event Management in Patients With Multiple Myeloma Receiving Talquetamab

EP: 6.GPRC5D-Related Oral Adverse Events in Multiple Myeloma

EP: 7.MonumenTAL-1: Proactive Management of Oral Toxicities

EP: 8.Multiple Myeloma: Educating Patients on Oral Toxicity Management

Now Viewing

EP: 9.Approaches for Managing Dermatologic Adverse Events from Talquetamab in Multiple Myeloma

EP: 10.Conclusions from MonumenTAL-1 Study in Multiple Myeloma

This is a video synopsis/summary of a Between The Lines series featuring Donna Catamero, ANP-BC, OCN, CCRC; Cesar Rodriguez, MD; and Saad Usmani, MD, MBA, FACP.

Talquetamab-induced dermatologic toxicities like rash (73% incidence) and palm/sole exfoliation arise early, mostly self-resolve within about a month, and infrequently prompt dose reductions (9%,≤2% discontinuations). Nail changes in 55% manifest later around 2 months. Although lasting throughout talquetamab therapy, nail toxicities are mostly aesthetic and rarely dose limiting (1% reductions, no discontinuations). Supportive measures for rash include barrier/moisturizing creams; antihistamines; topical/systemic steroids; and patient education on skin care, preventing infections, and prompt reporting of problems. For nail changes, nail hardeners, topical vitamin E, antibiotic ointments, nail trimming, moisture maintenance, avoiding tight shoes, hand sanitizer moderation, and moisturizing may help. Although they are mostly low grade, recognizing and quickly managing dermatologic adverse events is key.

Video synopsis is AI generated and reviewed by Cancer Network® editorial staff.